Assessment of diabetes screening by general practitioners in France: The EPIDIA Study

Diabetic Medicine

Volumn 23, Issue 7, 2006, Pages 803-807

  Cogneau, J ^a,b   Balkau, B ^c   Weill, A ^d   Liard, F ^d   Simon, D ^d  

^a Réseau EPI Qualiso ^*  (France)

^b Réseau EPI Qualiso   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Diabetes risk factors; Diabetes screening; General practice; Impaired fasting glucose; Undiagnosed diabetes

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; BODY MASS; CONSULTATION; CONTROLLED STUDY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FRANCE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; SCREENING;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; FEMALE; FRANCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS;

EID: 33748578358     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01877.x     Document Type: Article

References (24)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Harris M, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
3. Harris M, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 2000; 16: 230-236.
4. Haffner S, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? J Am Med Assoc 1990; 263: 2893-2898.
5. United Kingdom Prospective Diabetes Study (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
6. United Kingdom Prospective Diabetes Study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.
7. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
8. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type 2 diabetes. Diabetologia 2002; 45: S13-S17.
9. Agence Nationale d'Accrédation et d'Evaluation en Santé. Principes de Dépistage du Diabète de Type 2. Paris: Agence Nationale d'Accrédaton et d'Evaluation en Santé, 2003: 1-159.
10. American Diabetes Association (ADA). Screening for type 2 diabetes. Diabetes Care 2005, 1999; 28: S5-S7.
11. World Health Organization (WHO). Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Geneva: World Health Organization, 1999: 59.
12. Biolam. Les Actes de Biologie Remboursés en 2001 et 2002 par le Régime Général d'Assurance Maladie. Available from: http://www.ameli.fr/244/DOC/1531/article.html (accessed September 2005).
13. Hirtzlin I, Fagot-Campagna A, Girard-Le Gallo I, Vallier N, Poutignat N, Weill A et al. Dépistage du diabète: les données de l'échantillon permanent des assurés sociaux, 2000-01. Rev Epidemiol Sante Publique 2004; 52: 119-126.
14. Lawrence JM, Bennett P, Young A, Robinson AM. Screening for diabetes in general practice: cross-population study. Br Med J 2001; 323: 548-551.
15. Silvera L, Simon D, Trutt B, Blanchon B, Parmentier M, Hecquard P. Description des diabétiques de type 2 d'Ile-de-France,gés de 70 ans au plus. Diabetes Metab 2000; 26: 69-76.
16. Costagliola D, Chwalow J, Simon D, Eschwege E. Some key factors in the clinical diagnosis of non-insulin-dependent diabetes: a multinational comparison. Diabetes Metab 1989; 15: 51-52.
17. United Kingdom Prospective Diabetes Study (UKPDS). XII. Differences between Asian, Afro-Caribbean and white Caucasian Type 2 diabetic patients at diagnosis of diabetes. Diabet Med 1994; 11: 670-677.
18. Ricordeau P, Weill A, Vallier N, Bourrel R, Schwartz D, Guilhot J et al. The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000? Diabetes Metab 2003; 29: 497-504.
19. Charles MA. Epidémiologie de l'obésité. In: Basdevant A, Guy-Grand B., eds. Médecine de l'Obésité. Paris: Médecine-Sciences Flammarion, 2004, 8-16.
20. Marques-Vidal P, Montaye M, Ruidavets JB, Amouyel P, Ferrieres J. Evolution and cost trends of antihypertensive and hypolipidaemic drug treatment in France. Cardiovasc Drugs Ther 2003; 17: 175-179.
21. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD et al. Relation of impaired fasting and post-load glucose with incidence of type 2 diabetes in a Dutch population: The Hoorn Study. J Am Med Assoc 2001; 285: 2109-2113.
22. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
23. Greaves CJ, Stead JW, Hattersley AT, Ewings P, Brown P, Evans PH. A simple pragmatic system for detecting new cases of type 2 diabetes and impaired fasting glycaemia in primary care. Fam Pract 2004; 21: 57-62.
24. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Int Med 2004; 140: 689-710.